213 related articles for article (PubMed ID: 36357168)
1. CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers.
Ayton S; Janelidze S; Kalinowski P; Palmqvist S; Belaidi AA; Stomrud E; Roberts A; Roberts B; Hansson O; Bush AI
J Neurol Neurosurg Psychiatry; 2023 Mar; 94(3):211-219. PubMed ID: 36357168
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. The Associations of Cerebrospinal Fluid Ferritin with Neurodegeneration and Neuroinflammation Along the Alzheimer's Disease Continuum.
Pan R; Luo S; Huang Q; Li W; Cai T; Lai K; Shi X;
J Alzheimers Dis; 2022; 88(3):1115-1125. PubMed ID: 35754266
[TBL] [Abstract][Full Text] [Related]
4. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
5. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
[TBL] [Abstract][Full Text] [Related]
6. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
Marizzoni M; Ferrari C; Babiloni C; Albani D; Barkhof F; Cavaliere L; Didic M; Forloni G; Fusco F; Galluzzi S; Hensch T; Jovicich J; Marra C; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ranjeva JP; Ribaldi F; Rolandi E; Rossini PM; Salvatore M; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB
Neurobiol Aging; 2020 May; 89():55-62. PubMed ID: 32029236
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying β-amyloid pathology.
Diouf I; Bush AI; Ayton S;
Neurobiol Dis; 2020 Jun; 139():104810. PubMed ID: 32087292
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
9. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
10. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease.
García-Escobar G; Puig-Pijoan A; Puente-Periz V; Fernández-Lebrero A; María Manero R; Navalpotro-Gómez I; Suárez-Calvet M; Grau-Rivera O; Contador-Muñana J; Cascales-Lahoz D; Duran-Jordà X; Boltes N; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas MD; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Padrós-Fluvià A; Peña-Casanova J; Sánchez-Benavides G
J Alzheimers Dis; 2023; 92(4):1303-1321. PubMed ID: 37038810
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
12. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology.
Diouf I; Fazlollahi A; Bush AI; Ayton S;
Neurobiol Dis; 2019 Apr; 124():335-339. PubMed ID: 30557658
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
15. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
16. Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment.
Clark AL; Weigand AJ; Thomas KR; Solders SK; Delano-Wood L; Bondi MW; Bernier RA; Sundermann EE; Banks SJ; Bangen KJ;
J Alzheimers Dis; 2021; 80(4):1451-1463. PubMed ID: 33682714
[TBL] [Abstract][Full Text] [Related]
17. Evidence that iron accelerates Alzheimer's pathology: a CSF biomarker study.
Ayton S; Diouf I; Bush AI;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):456-460. PubMed ID: 28939683
[TBL] [Abstract][Full Text] [Related]
18. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
[TBL] [Abstract][Full Text] [Related]
19. Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age.
Ayton S; Janelidze S; Roberts B; Palmqvist S; Kalinowski P; Diouf I; Belaidi AA; Stomrud E; Bush AI; Hansson O
Prog Neurobiol; 2021 Mar; 198():101904. PubMed ID: 32882319
[TBL] [Abstract][Full Text] [Related]
20. Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.
Bridel C; Somers C; Sieben A; Rozemuller A; Niemantsverdriet E; Struyfs H; Vermeiren Y; Van Broeckhoven C; De Deyn PP; Bjerke M; Nagels G; Teunissen CE; Engelborghs S
Brain; 2022 Nov; 145(11):4056-4064. PubMed ID: 35026840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]